Xenikos Enrolls First Patient in Global Pivotal Phase III Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

0
226
Xenikos B.V. announced the enrolment of the first patient in a global pivotal Phase III clinical study designed to evaluate T-Guard® versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplant.
[Xenikos B.V.]
Press Release